Cancer-related anemia and recombinant human erythropoietin - An updated overview

Nature Clinical Practice Oncology

Volumn 3, Issue 3, 2006, Pages 152-164

  Bohlius, Julia ^a   Weingart, Olaf ^a   Trelle, Sven ^c   Engert, Andreas ^b  

^a Cochrane Haematological Malignancies Group ^*  (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Anemia; Cancer; Darbepoetin; Erythropoietin; Thromboembolic

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PLATINUM DERIVATIVE; PREDNISOLONE; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE; VINCRISTINE;

ANEMIA; BLEEDING; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; HEART DISEASE; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOXIA; LUNG EMBOLISM; META ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS; TREATMENT INDICATION; TUMOR GROWTH;

ANEMIA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; NEOPLASMS; PRACTICE GUIDELINES; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 33645334937     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0451     Document Type: Review

References (92)

1. Ludwig H et al. (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40: 2293-2306
2. Knight K et al. (2004) Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116 (Suppl 7A): S11-S26
3. Groopman F and Itri LM (1999) Chemotherapy-induced anemia in adults:iNcidence and treatment. J Natl Cancer Inst 91: 1616-1634
4. Spivak LI (2005) The anaemia of cancer:dEath by a thousand cuts. Nat Rev Cancer 5: 543-555
5. Miller CB et al. (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322: 1689-1692
6. Wood R and Hrushesky WJ (1995) Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 95: 1650-1659
7. Ludwig H and Strasser K (2001) Symptomatology of anemia. Semin Oncol 28: 7-14
8. Cella D (1997) The Functional Assessment of Cancer Therapy - Anemia (FACTAn) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34: 13-19
9. Holzner B et al. (2002) The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 13: 965-973
10. Lind M et al. (2002) The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 86: 1243-1249
11. Vogelzang N et al. (1997) Patient, caregiver, and oncologist perceptions of cancer related fatigue: Results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34: 4-12
12. Ahlberg K et al. (2003) Assessment and management of cancer related fatigue in adults. Lancet 362: 640-650
13. Mock V (2004) Evidence based treatment for cancer-related fatigue. J Natl Cancer Inst Monogr 112-118
14. Caro J et al. (2001) Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 91: 2214-2221
15. Vaupel P and Mayer A (2005) Hypoxia and anemia: Effects on tumor biology and treatment resistance. Transfus Clin Biol 12: 5-10
16. Schrijvers D et al. (1999) Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs 10: 147-153
17. 2 predicts survival in advanced cancer of the uterine cervix. Radiothe Oncol 26: 45-50
18. Kelleher DK et al. (1996) Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 56: 4728-4734
19. Thews O et al. (1998) Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy induced anaemia. Br J Cancer 78: 752-756
20. Silver DF and Pver MS (1999) Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 73: 280-284
21. Thews O et al. (2001) Erythropoietin restores the anemia induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 61: 1358-1361
22. Stuben G et al. (2003) Erythropoietin restores the anemia induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 55: 1358-1362
23. Goodnough LT (2005) Risks of blood transfusion. Anesthesiol Clin North America 23: 241-252
24. Engert A (2000) Recombinant human erythropoietin as an alternative to blood transfusion in cancer related anaemia. Dis Manage Health Outcomes 8: 259-272
25. Toy P et al. (2005) Transfusion related acute lung injury: Definition and review. Crit Care Med 33: 721-726
26. Goodnough LT et al. (1999) Transfusion medicine:fIrst of two parts blood transfusion. N Engl J Med 340: 438-447
27. Blajchman MA and Hebert B (2001) Red blood cell transfusion strategies. Transfus Clin Biol 8: 207-210
28. Hill SR et al. (2006) Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. The Cochrane Database of Systematic Reviews, Issue 1, Art. No CD002042
29. Hebert B et al. (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 340: 409-417
30. Murphy MF et al. (2001) Guidelines for the clinical use of red cell transfusions. Br J Haematol 113: 24-31
31. Simon TL et al. (1998) Practice parameter for the use of red blood cell transfusions:dEveloped by the Red Blood Cell Administration Practice Guideline Development Task Force of the College of American Pathologists. Arch Pathol Lab Med 122: 130-138
32. Lai PI et al. (1986) Structural characterization of human erythropoietin. J Biol Chem 261: 3116-3121
33. Koury ST et al. (1988) Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 71: 524-527
34. Koury ST et al. (1991) Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 77: 2497-2503
35. D'Andrea AD et al. (1989) Expression cloning of the murine erythropoietin receptor. Cell 57: 277-285
36. Koury MJ and Bondurant MC (1990) Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 248: 378-381
37. Goldwasser E et al. (1974) On the mechanism of erythropoietin induced differentiation:tHe role of sialic acid in erythropoietin action. J Biol Chem 249: 4202-4206
38. Procrit epoetin alfa full prescribing information [http//www.orthobiotech.com/common/prescribing_information/ROCRITEF/ ProcritBooklet.pdf]
39. Roche K package leafeat [http//www.rocheuk.com/productDB/Documents/rx/ pil/Recormon_PS_PL.pdf]
40. Aranesp® (darbepoetin alfa) prescribing information [http//www.aranesp.com/pdf/aranesp_P.pdf]
41. Egrie CJ et al. (2003) Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31: 290-299
42. Morreale A et al. (2004) Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin 20: 381-395
43. Halstenson CE et al. (1991) Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50: 702-712
44. Storring PL et al. (1998) Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 100: 79-89
45. Gaspy J et al. (2005) Final results of a phase 3, randomized, open label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) versus epoetin alfa 40000 U weekly (QW) in patients with chemotherapy-induced anemia (CIA) [abstract 8125]. J Clin Oncol 23
46. Cazzola M et al. (2003) Once weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122: 386-393
47. Rodgers G et al. (online 2005) Cancer-and treatment related anemia: OCI Clinical Practice Guidelines in Oncology 22005[2.2005] [www.nccn.org/ professionals/physician_gls/PF/anemia.pdf, Comprehensive Cancer Network] (accessed 27 January 2006)
48. Waltzman RJ et al. (2005) Final haematologic results: Epoetin alfa (DP) 40000 U OW vs darbepoetin alfa (DARB) 200 μg Q2W in anemic cancer patients (pts) receiving chemotherapy (CT) [abstract 8030]. Proc Am Soc Clin Oncol 23: A736s
49. Weingart O et al. (2005) Is the evidence cited in evidence based guidelines constructive and sufficient for the development of adapted guidelines 3rd Guideline International Network Conference, December 2005. Lyon:GUidelines International Network.
50. Rizzo D et al. (2002) Use of epoetin in patients with cancer:eVidence based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 4083-4107
51. Bokemeyer C et al. (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40: 2201-2216
52. Quirt I et al. and the Systemic Treatment Disease Site Group. (2005) The role of erythropoietin in the management of cancer patients with nonhematologic malignancies receiving chemotherapy [http//www.guideline.gov/summary/summary.aspxss=14doc_id=7217&tring] (accessed 27 January 2006)
53. Seidenfeld J et al. (2001) Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93: 1204-1214
54. Bottomley A et al. (2002) Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? Lancet Oncol 3: 145-153
55. Bohlius J et al. Erythropoietin for patients with malignant disease. The Cochrane Database of Systematic Reviews, Issue 3, Art. No CD003407
56. Littlewood TJ et al. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865-2874
57. Bohlius J et al. (2005) Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive metaanalysis. J Natl Cancer Inst 97: 489-498
58. Clark O et al. (2002) Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer 2: 23
59. Vansteenkiste J et al. (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211-1220
60. Hedenus M et al. (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122: 394-403
61. Ludwig H et al. (1994) Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84: 1056-1063
62. Witzig TE et al. (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23: 2606-2617
63. Gaspy J et al. (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218-1234
64. Demetri G et al. (1998) Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 16: 3412-3425
65. Cebrilove LI et al. (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients:iMprovements in hemoglobin and quality of life are similar to three times weekly dosing. J Clin Oncol 19: 2875-2882
66. Shasha D et al. (2003) Once weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 98: 1072-1079
67. Osterborg A et al. (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20: 2486-2494
68. Boogaerts M et al. (2003) Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 88: 988-995
69. Aaronson KI (1991) Methodologic issues in assessing the quality of life in cancer patients. Cancer 67: 844-850
70. Henke M et al. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy:rAndomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260
71. Leylandednes B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4: 459-460
72. Leylandednes B et al. (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving firstline chemotherapy: a survival study. J Clin Oncol 23: 5960-5972
73. Luksenburg H et al. (2004) FDA Oncologic Drugs Advisory Committee briefing document:SAfety concerns associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.F, for the treatment of anemia associated with cancer chemotherapy, FDA. [http//www.fda.gov/ohrms/dockets/ac/04/briefing/4037b2.htm] (accessed 22 June 2005)
74. Acs G et al. (2001) Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61: 3561-3565
75. Arcasoy MO et al. (2002) Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 82: 911-918
76. Ellkmann W and Wagner K (2004) Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 83: 673-686
77. Arcasoy MO et al. (2005) Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res 11: 20-27
78. Rosen FR et al. (2003) Multicenter randomized phase II study of paclitaxel (1 hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 9: 1689-1697
79. Machtay M et al. (2004) Definitive radiotherapy - erythropoietin for squamous cell carcinoma of the head and neck:pReliminary report of RTOG 9903. Int J Radiat Oncol Biol Phys 60 (Suppl 1): S132
80. Antonadou D et al. (2001) Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies:fInal results of a randomized phase III study. Eur J Cancer 37 (Suppl 6): S144
81. Blohmer LU et al. (2004) Results with sequential adjuvant chemoradiotherapy [abstract #447DP]. Ann Oncol 15 (Suppl 3)
82. Besarab A et al. (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590
83. Wun T et al. (2003) Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 98: 1514-1520
84. 3 integrin receptor activation and P selectin expression during platelet recruitment: Down regulation by aspirin ex vivo. Blood 99: 3978-3984
85. Stohlawetz PJ et al. (2000) Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 95: 2983-2989
86. Nowrousian MR et al. (1996) rh-Erythropoietin in Cancer Supportive Treatment, 1334 New York: Marcel Dekker
87. Abels R (1993) Erythropoietin for anemia in cancer patients. Eur J Cancer 29A (Suppl 2): S2-S8
88. Case DC et al. (1993) Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85: 801-806
89. Henry DH et al. (1995) Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1: 252-260
90. Oberhoff C et al. (1998) Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 9: 255-260
91. Chang J et al. (2005) Once weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 23: 2597-2605
92. Savonije IJ et al. (2005) Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum based chemotherapy: results of a multicenter randomised controlled trial. Eur J Cancer 41: 1560-1569